Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 165

Sort by

Sort Order Select

Journal Articles

Rbm38 deficiency impairs erythroid heme biosynthesis and induces porphyria via reduced ferrochelatase expression

Blood (2025) 146 (25): 3106–3123.

https://doi.org/10.1182/blood.2025028783

Published: 2025

Includes: Supplemental data

Journal Articles

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Blood (2025) 146 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2025-LBA-2

Published: 2025

Journal Articles

Identification of a development-restricted, megakaryocyte-primed population of hematopoietic progenitor cells during fetal and early postnatal development

Ryan Mack, Rohit Thalla, Lei Zhang, Kanak Joshi, Wei Wei, Peter Breslin, Jiwang Zhang

Blood (2025) 146 (Supplement 1): 4936.

https://doi.org/10.1182/blood-2025-4936

Published: 2025

Journal Articles

CD27, CD62L and ESAM define a multipotent progenitor population with megakaryocytic potential

Ryan Mack, Rohit Thalla, Lei Zhang, Kanak Joshi, Peter Breslin, Wei Wei, Jiwang Zhang

Blood (2025) 146 (Supplement 1): 4935.

https://doi.org/10.1182/blood-2025-4935

Published: 2025

Journal Articles

A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with persistent or chronic immune thrombocytopenia

Chen Yunfei, ZePing Zhou, Hu Zhou, Ruibin Huang, Zhenyu Yan, Jun Peng, Ming Hou, James Bussel, Alexander Zukiwski, Junping Chen, Lei Zhang

Blood (2025) 146 (Supplement 1): 3035.

https://doi.org/10.1182/blood-2025-3035

Published: 2025

Journal Articles

Sequence-based artificial intelligence-guided inhibitory peptides to counteract AAV neutralizing antibodies in gene therapy

Bingqi Xu, Xiaolei Pei, Dandan Yu, Xin Zhang, Siwei Yu, Lei Zhang

Blood (2025) 146 (Supplement 1): 279.

https://doi.org/10.1182/blood-2025-279

Published: 2025

Journal Articles

Low dose AAV8-FVIII gene therapy on Chinese severe Hemophilia A patients with sustainable efficacy and safety

Wei Liu, Xinyue Dai, Feng Xue, Chen Yunfei, Xiaofan Liu, Rongfeng Fu, Renchi Yang, Lei Zhang

Blood (2025) 146 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2025-4317

Published: 2025

Journal Articles

Targeting adss overcomes venetoclax resistance in TP53-mutated acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 213.

https://doi.org/10.1182/blood-2025-213

Published: 2025

Journal Articles

Multi-omics unveils ER stress-driven pDC-like leukemia stem cells in pDC-AML

Xingcheng Yang, Juan Peng, Ling Ma, Lei Zhang, Yicheng Zhang, Xia Mao, Jue Wang, Jia Wei

Blood (2025) 146 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2025-1693

Published: 2025

Journal Articles

Pharmacological targeting of CTPS1 elicits macrophage-mediated anti-leukemia immunity

Meng Liu, Lei Zhang, Xin He, Haojie Dong, Yang Li, Shuaishuai Ge, Guohua Wu, Umesh Yadav, wei chen, Pinghui Feng, Guido Marcucci, Ling Li

Blood (2025) 146 (Supplement 1): 1490.

https://doi.org/10.1182/blood-2025-1490

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Blood (2025) 146 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2025-3587

Published: 2025

Journal Articles

Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent/chronic immune thrombocytopenia in the long-term extension period of the Phase 3 LUNA3 study

David Kuter, Lei Zhang, Waleed Ghanima, Yoshitaka Miyakawa, Yu Hu, David Gomez-Almaguer, Matias Cordoba, Marek Wardecki, Larissa Mege, Meredith Foster, Ahmed Daak, Howard Liebman

Blood (2025) 146 (Supplement 1): 1260.

https://doi.org/10.1182/blood-2025-1260

Published: 2025

Journal Articles

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Blood (2025) 146 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2025-2039

Published: 2025

Journal Articles

Venetoclax plus azacitidine vs. traditional chemotherapy in younger patients with Acute Myeloid Leukemia: A single-center real-world study

Zi-Yuan Nie, Xiao-Lei Zhang, Jinhai Ren, Xiao-Ling Guo

Blood (2025) 146 (Supplement 1): 5175.

https://doi.org/10.1182/blood-2025-5175

Published: 2025

Journal Articles

Dual-armoring of CLL-1 CAR-T cells with IL-18 and an RQR8 suicide switch enhances efficacy and safety in Acute Myeloid Leukemia

Wenyi Lu, Bing Cao, Xin Jin, Yuanyuan Hao, Lei Zhang, Wei Cheng, Wei Li, Zhenxin Zhao, Zhoufeng Huang, Wenyan Li, Yuanbo Liu, Mingfeng Zhao, Zunmin Zhu

Blood (2025) 146 (Supplement 1): 4124.

https://doi.org/10.1182/blood-2025-4124

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2025-3896

Published: 2025

Journal Articles

Targeting PRMT7 enhances the anti-AML immunity by regulating MHC-I

Shuaishuai Ge, Kaixiu luo, Lei Zhang, Meng Liu, Xin He, Guohua Wu, Yang Li, Umesh Yadav, Haojie Dong, Shengli Xue, Jian Jin, Ling Li

Blood (2025) 146 (Supplement 1): 387.

https://doi.org/10.1182/blood-2025-387

Published: 2025

Journal Articles

Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP)

Nicola Cooper, Waleed Ghanima, Francesco Zaja, Lei Zhang, Yoshitaka Miyakawa, Marie Luise Hütter-Krönke, Matias Cordoba, Mattea Orsini, Imene Gouia, Ahmed Daak, Howard Liebman

Blood (2025) 146 (Supplement 1): 1254.

https://doi.org/10.1182/blood-2025-1254

Published: 2025

Journal Articles

Efficacy and safety of hetrombopag in the treatment of Pediatric immune thrombocytopenia: A Real-World Observational Study

Aixue Liu, Sun Ting, Lei Zhang

Blood (2025) 146 (Supplement 1): 3047.

https://doi.org/10.1182/blood-2025-3047

Published: 2025

Journal Articles

A proteomics-driven machine learning tool for distinguishing ET from pre-PMF

Qing Wen, Sun Ting, Renchi Yang, Chen Yunfei, Lei Zhang

Blood (2025) 146 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2025-1973

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rbm38 deficiency impairs erythroid heme biosynthesis and induces porphyria via reduced ferrochelatase expression

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Identification of a development-restricted, megakaryocyte-primed population of hematopoietic progenitor cells during fetal and early postnatal development

CD27, CD62L and ESAM define a multipotent progenitor population with megakaryocytic potential

A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with persistent or chronic immune thrombocytopenia

Sequence-based artificial intelligence-guided inhibitory peptides to counteract AAV neutralizing antibodies in gene therapy

Low dose AAV8-FVIII gene therapy on Chinese severe Hemophilia A patients with sustainable efficacy and safety

Targeting adss overcomes venetoclax resistance in TP53-mutated acute myeloid leukemia

Multi-omics unveils ER stress-driven pDC-like leukemia stem cells in pDC-AML

Pharmacological targeting of CTPS1 elicits macrophage-mediated anti-leukemia immunity

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent/chronic immune thrombocytopenia in the long-term extension period of the Phase 3 LUNA3 study

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Venetoclax plus azacitidine vs. traditional chemotherapy in younger patients with Acute Myeloid Leukemia: A single-center real-world study

Dual-armoring of CLL-1 CAR-T cells with IL-18 and an RQR8 suicide switch enhances efficacy and safety in Acute Myeloid Leukemia

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Targeting PRMT7 enhances the anti-AML immunity by regulating MHC-I

Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP)

Efficacy and safety of hetrombopag in the treatment of Pediatric immune thrombocytopenia: A Real-World Observational Study

A proteomics-driven machine learning tool for distinguishing ET from pre-PMF

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only